
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly's strong performance in the second quarter of 2025, characterized by both top and bottom-line growth and an increase in fiscal year guidance, signifies robust financial health. Notably, the company's Mounjaro product experienced impressive international sales growth of 60% quarter-over-quarter, bolstered by successful market entries in Brazil, Mexico, and India. Additionally, the anticipated launch of orforglipron is expected to further enhance Lilly's position in the GLP-1 market with its innovative oral formulation, potentially driving additional revenue streams.
Bears say
The analysis of Eli Lilly's stock indicates a number of critical concerns that support a negative outlook. There are significant risks associated with potential pricing and rebate pressures, coupled with a disappointing trajectory for tirzepatide prescriptions, and its inability to demonstrate cardiac outcome benefits in key patient populations. Additionally, the negative impact on Zepbound prescriptions and the competitive threat posed by orforglipron, which outperforms expectations for similar products, further exacerbate these challenges, leading to lowered sales forecasts and overall market uncertainty.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares